Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries.

ABSTRACT: Even for products centrally approved, each European country is responsible for national market access after European Medicines Agency (EMA) approval. This step can result in inequalities in terms of access, due to different opinions about the therapeutic value assessed by Health Technology Assessment (HTA) bodies. This study aims to provide a comparative analysis of HTA recommendations issued by EU countries (France, Germany, and Italy) for new neurological drugs following EMA approval. In the reference period, we identified 11 innovative medicines authorized in Europe for five neurological diseases (cerebral adrenoleukodystrophy, spinal muscular atrophy, metachromatic leukodystrophy, migraine, and polyneuropathy in patients with hereditary transthyretin amyloidosis), including eight drugs

SUBMITTER: Gozzo L 

PROVIDER: S-EPMC8854989 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature